V.HEART Discovery
Select candidates with human QT prolongation predictions
Platform · Cloud SaaSCompany source
Company profile
About ELEM Biotech
ELEM Biotech is a healthcare technology company specializing in cardiac digital twin platforms that transform drug development and clinical decision-making. The company's flagship products, V.HEART Trials and V.HEART Discovery, enable pharmaceutical companies, clinical research organizations, medical device manufacturers, and healthcare providers to simulate virtual clinical trials and predict cardiac safety risks before human testing. V.HEART Discovery focuses on early-stage cardiac safety prediction, allowing researchers to screen drug candidates for QT prolongation and arrhythmic risk across concentration ranges up to 50x effective doses. V.HEART Trials enables full clinical trial simulation on the cloud, allowing users to configure virtual patient populations, apply treatments, and analyze results in hours rather than months. The technology combines patient-specific data, high-performance physics-based simulation, and advanced AI to create virtual human populations that reflect real-world diversity. ELEM's platforms help clients reduce R&D costs by up to 80%, decrease failure rates by 30%, and generate scientific evidence for regulatory submissions. The company serves multiple healthcare sectors including pharma, CROs, regulators, medical device companies, and health delivery organizations, supporting applications from hit-to-lead optimization to precision medicine and value-based healthcare initiatives.
Company description ELEM Biotech official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at ELEM Biotech?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiac arrhythmia
- Cardio-oncology
- Cardiovascular disease
- Proarrhythmic risk
- QT prolongation
Who it serves
- Clinical Research Organizations (CROs)
- Health Delivery Organizations
- Medical device manufacturers
- Pharmaceutical companies
- Regulators
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope · Spain · United Kingdom
Company sourceOfficial website
Company milestones
Platform expansion
Published AI-enhanced cardiac digital twins paper on drug proarrhythmic risk assessment. Conducted cardio-oncology safety trial with 120 virtual patients. Completed pacing optimization study using 15 real patient digital twins expanded to 150 synthetic patients. Developed respiratory drug delivery optimization for 5,000 virtual population from 100 anatomies.
Partnerships
Recorded partners
- Academic institutions
- Clinical partners
- Regulatory bodies
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
V.HEART Trials
Configure, run and analyse virtual clinical trials on the cloud
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study.Regulatory toxicology and pharmacology : RTP · Jun 1, 2026
Can in silico models predict drug-induced cardiac risk in vulnerable populations?Toxicology reports · Jun 1, 2026
Advancing aortic stenosis assessment: Validation of fluid-structure interaction models against 4D flow MRI data.The Journal of physiology · Apr 4, 2026
Incidental findings and duty-of-care protocols in cardiovascular magnetic resonance among older adults: a prospective population-based study from MyoFit46.The lancet. Healthy longevity · Feb 1, 2026
Higher Life-Course Blood Pressure Associates With Reduced Myocardial Perfusion in Older Age: Insights From MyoFit46.Circulation. Cardiovascular imaging · Feb 1, 2026
Electromechanical computational modeling of heart failure provides extensive analysis of cardiac pathophysiological features.Biomechanics and modeling in mechanobiology · Jan 13, 2026
Clinical validation
Clinical-trial records
Virtual Twins as Tools for Personalized Clinical Care in Renal Denervation - Pilot StudyNCT07462572 · Sponsor · NOT YET RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
80% cost savings
Reducing R&D expenses by identifying cardiac risks earlier
30% risk reduction
Reducing failure rates with advanced cardiac safety predictions
5x virtual cohort expansion
Created 120 virtual cardio-oncology patients from real cohort
100x concentration testing
Screen molecules up to 100x effective concentrations for QT prolongation
Hours vs months
Test multiple scenarios in hours instead of months
Cardio-Oncology Clinical Trial Client
Accelerate cardiac safety assessment for new cancer treatments
5x matching virtual cardio-oncology cohort of 120 gender-balanced Virtual Patients delivered within days, enabling prevention of adverse events and avoiding recruitment delays
MedTech Company (Paediatrics Pacing)
Pacing optimization for pediatric patients using digital twins to assess device therapy efficacy
Studied 10 different pacing scenarios for each of 15 real patients, then developed synthetic population of 150 additional patients to fill study gaps
Respiratory Drug Delivery Client
Maximize efficacy of respiratory nasal spray drug delivery
Created virtual population of 5,000 from 100 detailed human respiratory anatomies, optimized drug delivery to target area with studies completed in days
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from ELEM Biotech
Recent articles published on ELEM Biotech's official website.
ELEM in National Geographic: Women’s Health and Digital Twins
Read on ELEM BiotechELEM Biotech at EUCROF26
Read on ELEM BiotechTurning Innovation into Real-World Impact – 1
Read on ELEM BiotechOne modelling framework, three pathways to heart failure
Read on ELEM BiotechElectromechanical computational modeling of heart failure provides extensive analysis of cardiac pathophysiological features
Read on ELEM Biotech07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.